Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

MLA

Stutterheim, Janine, et al. “Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol.” Blood, vol. 136, no. Supplement 1, Nov. 2020, pp. 41–42. EBSCOhost, https://doi.org/10.1182/blood-2020-134303.

APA

Stutterheim, J., van der Sluis, I. M., De Lorenzo, P., Alten, J., Ancliff, P., Attarbaschi, A., Brethon, B., Biondi, A., Campbell, M., Cazzaniga, G., Escherich, G., Ferster, A., Kotecha, R. S., Lausen, B., Li, C. K., Lo Nigro, L., Locatelli, F., Marschalek, R., Schrappe, M., … Pieters, R. (2020). Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol. Blood, 136(Supplement 1), 41–42. https://doi.org/10.1182/blood-2020-134303

Chicago

Stutterheim, Janine, Inge M. van der Sluis, Paola De Lorenzo, Julia Alten, Philip Ancliff, Andishe Attarbaschi, Benoit Brethon, et al. 2020. “Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol.” Blood 136 (Supplement 1): 41–42. doi:10.1182/blood-2020-134303.